Breadcrumb

[A16-35] Nivolumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2016-06-08 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 624 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A19-11] Nivolumab (renal cell carcinoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A18-53] Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A18-40] Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed

[A17-27] Nivolumab (melanoma) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)
Status: Commission completed

[A17-24] Nivolumab (squamous cell carcinoma of the head and neck) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A16-76] Nivolumab (Hodgkin lymphoma) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A16-68] Nivolumab (melanoma) - Addendum to Commission A16-35
Status: Commission completed

[A16-25] Nivolumab (new therapeutic indication) – Benefit assessment according to §35a SGB V
Status: Commission completed

[A16-24] Nivolumab (new therapeutic indication) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A15-32] Nivolumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed

[A15-27] Nivolumab – Benefit assessment according to §35a Social Code Book V (dossier assessment)
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2016-09-15 Extract of dossier assessment 624 kBPDFdownload file
2016-09-15 Dossier assessment (German version) 2 MBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Nivolumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V [PDF, 624 kB]

Federal Joint Committee (G-BA)

2016-12-15 A G-BA decision was published.

G-BA documents on this decision

Press releases

2016-09-15 Nivolumab plus ipilimumab in melanoma: added benefit in certain patients



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close